Baird Financial Group
PTCT icon

Baird Financial Group’s PTC Therapeutics PTCT Stock Holding History

Baird Financial Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
+2,684
New +$194K ﹤0.01% 1847

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Baird Financial Group's PTCT Position: Q2 2026 in Review

Baird Financial Group opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 2,684 shares worth $219K. The stake represents ﹤0.01% of the portfolio and ranks #1847 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Baird Financial Group held 2,684 shares of PTC Therapeutics worth $219K as of Q2 2026.
  • PTC Therapeutics was a new Baird Financial Group position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1847 holding.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.